Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2012, Article ID 630182, 7 pages
http://dx.doi.org/10.1155/2012/630182
Review Article

Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer’s Disease Treatment: Rethinking the Current Strategy

1Le Groupe de Recherche sur le Système Nerveux Central, Département de Physiologie, Université de Montréal, Montréal, QC, Canada
2Douglas Mental Health University Institute, McGill University, Department of Psychiatry, Montreal, Quebec, Canada
3UTSA Neurosciences Institute and Department of Biology, College of Sciences, University of Texas at San Antonio, San Antonio, TX, USA
4Department of Pathology, Case Western Reserve University, Cleveland, OH, USA

Received 7 October 2011; Accepted 18 November 2011

Academic Editor: Paula Moreira

Copyright © 2012 Siddhartha Mondragón-Rodríguez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [29 citations]

The following is the list of published articles that have cited the current article.

  • Diana Seidel, Dana Krinke, Heinz-Georg Jahnke, Anika Hirche, Daniel Kloß, Till G. A. Mack, Frank Striggow, and Andrea Robitzki, “Induced Tauopathy in a Novel 3D-Culture Model Mediates Neurodegenerative Processes: A Real-Time Study on Biochips,” PLoS ONE, vol. 7, no. 11, 2012. View at Publisher · View at Google Scholar
  • Biao Cheng, Hao Gong, Hongwen Xiao, Robert B. Petersen, Ling Zheng, and Kun Huang, “Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases,” Biochimica et Biophysica Acta (BBA) - General Subjects, 2013. View at Publisher · View at Google Scholar
  • Wolfgang Froestl, Andrea Pfeifer, and Andreas Muhs, “Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs,” Journal Of Alzheimers Disease, vol. 34, no. 1, pp. 1–114, 2013. View at Publisher · View at Google Scholar
  • Siddhartha Mondragón-Rodríguez, George Perry, Xiongwei Zhu, Paula I. Moreira, Mariana C. Acevedo-Aquino, and Sylvain Williams, “Phosphorylation of Tau Protein as the Link between Oxidative Stress, Mitochondrial Dysfunction, and Connectivity Failure: Implications for Alzheimer’s Disease,” Oxidative Medicine and Cellular Longevity, vol. 2013, pp. 1–6, 2013. View at Publisher · View at Google Scholar
  • Mondragón-Rodríguez, Perry, Luna-Muñoz, Acevedo-Aquino, and Williams, “Phosphorylation of tau protein at sites Ser396-404 is one of the earliest events in Alzheimer's disease and Down syndrome,” Neuropathology and Applied Neurobiology, vol. 40, no. 2, pp. 121–135, 2014. View at Publisher · View at Google Scholar
  • Xiang-Hong Zeng, Qian-Qian Li, Qian Xu, Fang Li, and Cun-Zhi Liu, “Acupuncture Mechanism and Redox Equilibrium,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, pp. 1–7, 2014. View at Publisher · View at Google Scholar
  • Elżbieta Miller, Agnieszka Morel, Luciano Saso, and Joanna Saluk, “Isoprostanes and Neuroprostanes as Biomarkers of Oxidative Stress in Neurodegenerative Diseases,” Oxidative Medicine and Cellular Longevity, vol. 2014, pp. 1–10, 2014. View at Publisher · View at Google Scholar
  • Peipei Wang, and Kan Ding, “Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease,” Protein and Peptide Letters, vol. 21, no. 10, pp. 1048–1056, 2014. View at Publisher · View at Google Scholar
  • Benjamin E. Blasspp. 1–574, 2015. View at Publisher · View at Google Scholar
  • Liang Zhang, Yu Yamazaki, Takahisa Kanekiyo, Guojun Bu, Benjamin Gateno, Kyeong-Ok Chang, Karl A. Nath, Emirhan Nemutlu, Petras Dzeja, Yuan-Ping Pang, Duy H. Hua, Song Zhang, Eugenia Trushina, Izumi Maezawa, Sergey Trushin, Paras Minhas, Matthew Pinto, Lee-Way Jin, Keshar Prasain, and Thi D.T. Nguyen, “Modulation of Mitochondrial Complex I Activity Averts Cognitive Decline in Multiple Animal Models of Familial Alzheimer's Disease,” EBioMedicine, vol. 2, no. 4, pp. 294–305, 2015. View at Publisher · View at Google Scholar
  • Elham Amini, Ehsan Nassireslami, Borna Payandemehr, Fariba Khodagholi, Forough Foolad, Sara Khalaj, Mostafa Pirali Hamedani, Leyla Azimi, and Mohammad Sharifzadeh, “Paradoxical role of PKA inhibitor on amyloidβ-induced memory deficit,” Physiology and Behavior, vol. 149, pp. 76–85, 2015. View at Publisher · View at Google Scholar
  • Benjamin E. Blass, “Drug Discovery and Development,” Basic Principles of Drug Discovery and Development, pp. 1–34, 2015. View at Publisher · View at Google Scholar
  • Lopatina, Fursov, Lavrentiev, Belova, Salmina, Uspenskaya, Komleva, Pozhilenkova, and Salmin, “Ligands of RAGE-proteins: Role in intercellular communication and pathogenesis of inflammation,” Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, vol. 70, no. 6, pp. 694–703, 2015. View at Publisher · View at Google Scholar
  • Siddhartha Mondragón Rodríguez, “The Use of Neuropathology in Alzheimer’s Disease,” International Clinical Pathology Journal, vol. 2, no. 5, 2016. View at Publisher · View at Google Scholar
  • Romina María Uranga, Natalia Paola Alza, Melisa Ailén Conde, Silvia Susana Antollini, and Gabriela Alejandra Salvador, “Phosphoinositides: Two-Path Signaling in Neuronal Response to Oligomeric Amyloid β Peptide,” Molecular Neurobiology, vol. 54, no. 5, pp. 3236–3252, 2016. View at Publisher · View at Google Scholar
  • Genevieve Evin, “Future Therapeutics in Alzheimer’s Disease: Development Status of BACE Inhibitors,” BioDrugs, vol. 30, no. 3, pp. 173–194, 2016. View at Publisher · View at Google Scholar
  • Antoine-Scott Badin, Cristina Tormo-Garcia, Paul Morrill, Henry Tu, Gwenael Pottiez, Clive W. Coen, Sara Garcia-Ratés, Catherine Heffner, and Susan A. Greenfield, “(I) Pharmacological profiling of a novel modulator of the α7 nicotinic receptor: Blockade of a toxic acetylcholinesterase-derived peptide increased in Alzheimer brains,” Neuropharmacology, vol. 105, pp. 487–499, 2016. View at Publisher · View at Google Scholar
  • George D. Wilson, and Brian Marples, “A New Use for an Old Treatment: Radiation Therapy and Alzheimer's Disease,” Radiation Research, vol. 185, no. 5, pp. 443–448, 2016. View at Publisher · View at Google Scholar
  • Wenrui Hao, and Avner Friedman, “Mathematical model on Alzheimer's disease,” BMC Systems Biology, vol. 10, no. 1, 2016. View at Publisher · View at Google Scholar
  • Tianfang Jiang, Qian Sun, and Shengdi Chen, “Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease,” Progress in Neurobiology, 2016. View at Publisher · View at Google Scholar
  • John W. Finley, and Song Gao, “ A Perspective on Crocus sativus L. (Saffron) Constituent Crocin: A Potent Water-Soluble Antioxidant and Potential Therapy for Alzheimer’s Disease ,” Journal of Agricultural and Food Chemistry, 2017. View at Publisher · View at Google Scholar
  • Seung-Hoon Yang, Jiyoon Kim, Hoyong Jung, Jung-Mi Hah, YoungSoo Kim, Dongkeun Kenneth Lee, Jisu Shin, Sejin Lee, and Seungyeop Baek, “Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice,” EMBO Molecular Medicine, vol. 9, no. 1, pp. 61–77, 2017. View at Publisher · View at Google Scholar
  • Siddhartha Mondragón-Rodríguez, George Perry, Fernando Peña-Ortega, and Sylvain Williams, “Tau, amyloid beta and deep brain stimulation: Aiming to restore cognitive deficit in alzheimer’s disease,” Current Alzheimer Research, vol. 14, no. 1, pp. 40–46, 2017. View at Publisher · View at Google Scholar
  • Andis Klegeris, Manpreet Bahniwal, and Jonathan P. Little, “High glucose enhances neurotoxicity and inflammatory cytokine secretion by stimulated human astrocytes,” Current Alzheimer Research, vol. 14, no. 7, pp. 731–741, 2017. View at Publisher · View at Google Scholar
  • Tatjana Momić, Tamara Lazarevic-Pašti, Andreja Leskovac, Sandra Petrovic, and Vesna Vasic, “Modulators of acetylcholinesterase activity: From Alzheimer's disease to anti-cancer drugs,” Current Medicinal Chemistry, vol. 24, no. 30, pp. 3283–3309, 2017. View at Publisher · View at Google Scholar
  • S. Mondragón-Rodríguez, G. Perry, and F. Peña-Ortega, “Tau Proteins,” Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders, pp. 145–160, 2017. View at Publisher · View at Google Scholar
  • Maja Jazvinšćak Jembrek, Neda Slade, Patrick R. Hof, and Goran Šimić, “The interactions of p53 with tau and Aß represent potential therapeutic targets for Alzheimer’s disease,” Progress in Neurobiology, 2018. View at Publisher · View at Google Scholar
  • Martín Macías, Peña-Ortega Fernando, Orta-Salazar Erika, Mondragón-Rodríguez Siddhartha, George Perry, Sylvain Williams, Salas-Gallardo Anahi, González-Pereyra Perla, Benito Ordaz, Aguilar-Vázquez Azucena, and Díaz-Cintra Sofía, “Phosphorylation of Tau protein correlates with changes in hippocampal theta oscillations and reduces hippocampal excitability in Alzheimer’s model,” Journal of Biological Chemistry, vol. 293, no. 22, pp. 8462–8472, 2018. View at Publisher · View at Google Scholar
  • Abhishek Ankur Balmik, and Subashchandrabose Chinnathambi, “Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimer's Disease,” Journal of Alzheimer's Disease, vol. 62, no. 4, pp. 1481–1493, 2018. View at Publisher · View at Google Scholar